Sugi Predict

Sugi Predict / Compounds / SCHEMBL21357414

SCHEMBL21357414

SCHEMBL21357414

COc1c[nH]c(=O)cc1-c1cc(Cl)ccc1-n1cc(C(F)(F)F)nn1

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ F11 P03951 19/20 0.51
▸ KLKB1 P03952 18/20 0.51
▸ CYP3A4 P08684 4/20 0.51
▸ F2 P00734 1/20 0.49
▸ F10 P00742 1/20 0.49
▸ CYP1A1 P04798 1/20 0.49
▸ PRSS1 P07477 1/20 0.49
▸ PRSS2 P07478 1/20 0.49
▸ CYP2C8 P10632 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ PRSS3 P35030 1/20 0.49
▸ NR1I2 O75469 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30325632 0.93 F11 (0.45) F11KLKB1CYP3A4F2F10
SCHEMBL29479321 0.86 F11 (0.49) F11KLKB1CYP3A4
SCHEMBL21357358 0.86 F11 (0.49) F11KLKB1CYP3A4
SCHEMBL24633487 0.86 F11 (0.41) F11KLKB1CYP3A4F2F10
SCHEMBL30995020 0.86 F11 (0.41) F11KLKB1CYP3A4F2F10
SCHEMBL29089481 0.85 F11 (0.40) F11KLKB1CYP3A4NR1I2
SCHEMBL30656620 0.85 F11 (0.40) F11KLKB1CYP3A4NR1I2
SCHEMBL24633283 0.84 F11 (0.53) F11KLKB1CYP3A4
SCHEMBL30325628 0.83 F11 (0.37) F11KLKB1CYP3A4F2F10
SCHEMBL29839752 0.83 F11 (0.40) F11KLKB1CYP3A4F2F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111770917-B Process for the preparation of two compounds 拜耳股份公司 2023-09-26 — — CN claimed
EP-3765452-B1 PREPARATIVE PROCESS OF TWO 4-{[(2S)-2-{4-[5-CHLORO-2-(1H-1,2,3-TRIAZOL-1-YL)PHENYL]-5-METHOXY-2-OXOPYRIDIN-1(2H)-YL}BUTANOYL]AMINO}-2-FLUOROBENZAMIDE DERIVATIVES BAYER AG (DE) 2022-04-13 — — EP claimed
CN-111770917-A Two 4- { [ (2S) -2- {4- [ 5-chloro-2- (1H-1,2, 3-triazol-1-yl) phenyl ] -5-methoxy-2-oxopyridin-1 (2H) -yl } butyryl ] amino } -2-fluorobenzamide derivatives 拜耳股份公司 2020-10-13 — — CN claimed
CN-116262736-B Novel oxo-pyridine compound and preparation method and application thereof 成都施贝康生物医药科技有限公司 2025-05-13 — — CN disclosed
CN-116262734-B Oxo-pyridine compound and preparation method and application thereof 成都施贝康生物医药科技有限公司 2025-05-13 — — CN disclosed
CN-116621742-B Novel preparation method of oxo-pyridine compound and key intermediate 成都施贝康生物医药科技有限公司 2025-05-06 — — CN disclosed
CN-118406037-B Triazole derivative and preparation method and application thereof 四川师范大学 2025-02-25 — — CN disclosed
CN-116082303-B Novel oxopyridines, intermediates and uses thereof 成都施贝康生物医药科技有限公司 2025-02-25 — — CN disclosed
CN-116283750-B Heterocyclic amide derivative and preparation method and application thereof 成都泰和伟业生物科技有限公司 2025-02-07 — — CN disclosed
CN-118406037-A Triazole derivative and preparation method and application thereof 四川师范大学 2024-07-30 — — CN disclosed
CN-118063457-A Pyridone compounds, preparation method thereof and application thereof in medicines 江苏恒瑞医药股份有限公司 2024-05-24 — — CN disclosed
WO-2022222960-A1 FXIA INHIBITOR AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND USE THEREOF 上海美悦生物科技发展有限公司 2022-10-27 — — WO disclosed
CN-112028877-B Alkoxy pyridone compound and preparation method and application thereof 江西济民可信集团有限公司 2021-11-26 — — CN disclosed
EP-3889147-A1 4-({(2S)-2-[4-{5-CHLORO-2-[4-(TRIFLUOROMETHYL)-1H-1,2,3-TRIAZOL-1-YL]PHENYL}-5-METHOXY-2-OXOPYRIDIN-1(2H)-YL]BUTANOYL}-AMINO)-2-FLUOROBENZAMIDE ACETONE AND ITS USE Bayer Aktiengesellschaft (DE) 2021-10-06 — — EP disclosed
EP-3889147-A1 4-({(2S)-2-[4-{5-CHLORO-2-[4-(TRIFLUOROMETHYL)-1H-1,2,3-TRIAZOL-1-YL]PHENYL}-5-METHOXY-2-OXOPYRIDIN-1(2H)-YL]BUTANOYL}-AMINO)-2-FLUOROBENZAMIDE ACETONE AND ITS USE Bayer Aktiengesellschaft (DE) 2021-10-06 — — EP disclosed
US-20210017152-A1 PREPARATIVE PROCESS BAYER AKTIENGESELLSCHAFT (DE) 2021-01-21 — — US disclosed
EP-3765452-A1 PREPARATIVE PROCESS OF TWO 4-{[(2S)-2-{4-[5-CHLORO-2-(1H-1,2,3-TRIAZOL-1-YL)PHENYL]-5-METHOXY-2-OXOPYRIDIN-1(2H)-YL}BUTANOYL]AMINO}-2-FLUOROBENZAMIDE DERIVATIVES Bayer Aktiengesellschaft (DE) 2021-01-20 — — EP disclosed
CN-112028877-A Alkoxy pyridone compound and preparation method and application thereof 江西济民可信集团有限公司 2020-12-04 — — CN disclosed
CN-111770917-A Two 4- { [ (2S) -2- {4- [ 5-chloro-2- (1H-1,2, 3-triazol-1-yl) phenyl ] -5-methoxy-2-oxopyridin-1 (2H) -yl } butyryl ] amino } -2-fluorobenzamide derivatives 拜耳股份公司 2020-10-13 — — CN disclosed
WO-2019175043-A1 PREPARATIVE PROCESS OF TWO 4-{[(2S)-2-{4-[5-CHLORO-2-(1H-1,2,3-TRIAZOL-1-YL)PHENYL]-5-METHOXY-2-OXOPYRIDIN-1(2H)-YL}BUTANOYL]AMINO}-2-FLUOROBENZAMIDE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2019-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210017152-A1 PREPARATIVE PROCESS F13A1, F13B, TUBA3C F11 12/4885KLKB1 3280/4885CYP3A4 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback